FRM
CCCC icon

Fox Run Management’s C4 Therapeutics CCCC Stock Holding History

Fox Run Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14,973
Closed -$69.2K – 835
2024
Q2 		$69.2K Sell
14,973
-26,759
-64% -$160K 0.01% 733
2024
Q1 		$341K Buy
+41,732
New +$323K 0.07% 492
2022
Q2 		– Sell
-8,926
Closed -$217K – 550
2022
Q1 		$217K Buy
+8,926
New +$217K 0.12% 388

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fox Run Management's CCCC Position: Q3 2024 in Review

Fox Run Management sold out of C4 Therapeutics (CCCC) in Q3 2024, closing a stake of 14,973 shares — an estimated $69.2K sold.

Fox Run Management first reported a position in CCCC in Q1 2022 and held it in 3 quarters. The position peaked at $341K in Q1 2024. 118 funds tracked by Wall St. Rank hold CCCC as of Q3 2024.

  • Fox Run Management reported no remaining C4 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Fox Run Management sold 14,973 C4 Therapeutics shares in Q3 2024, an estimated $69.2K.
  • Fox Run Management first reported a position in C4 Therapeutics in Q1 2022 and held it in 3 quarters.
  • Fox Run Management's C4 Therapeutics position peaked at $341K in Q1 2024.
  • 118 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2024.

Based on Fox Run Management's 13F filing for Q3 2024, filed 12 Nov 2024.